

Paten 1 Trademark Office COMMesciONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

1..........

1

	FILING DATE			FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
SERIAL NUMBER		07/9 8 TUL	MANEN	-	1240-1-017
r	,017 047	07798 100	O'FINCIN		EXAMINER

HM22/0517

DAVID A JACKSON KLAUBER & JACKSON 411 HACKENSACK AVENUE HACKENSACK NJ 07601

L

F 1	240-1-017				
EXAM	EXAMINER				
ARTURN, M	PAPER NUMBER				
	7				
DATE MAILED:					

05/17/99

Please find below a communication from the EXAMINER in charge of this application $_{\it F}$ Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication should be directed to at telephone number (703)30%-0666 $\,$.

Marianne P. Allen
MARIANNE P. ALLEN
PRIMARY EXAMINER
GROUP-1000
AUGUS

09/05019

Application No.:

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)

-					
П	 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990. 				
Ш	This application does not contain, as a separate part of the disclosure on paper copy, a *Sequence Listing* as required by 37 C.F.R. 1.821(c).				
u	 A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). 				
M	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."				
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).				
	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).				
П	7. Other:				
Ч					
Applicant Must Provide:					
X	An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".				
Ί.	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry				
X	An initial or substitute paper copy of the dequation and the specification.				
M	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or				
F	` 1.825(b) or 1.825(d). or questions regarding compliance to these requirements, please contact:				
E	or Rules Interpretation, call (703) 308-4216				
E	or CRF Submission Help, call (703) 308-4212				
F	or Patentin software help, call (703) 308-6856 PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE				

Raw Sequence Listing Error Summary

		SUCCESSED CORRECTION SERIAL NUMBER: 09/056,0/9
	ERROR DETECTED	SUGGESTED CORRECTION SERIAL NUMBER:
		THE THE PART OF TH
ATTN:	NEW RULES CASES: FL	EASE DISREGARD ENGLISH ALT IN "Wrapped" down to the next line. The number/lext at the end of each line "wrapped" down to the next line.
1	Wrapped Nucleics	
		This may occur if your file was retrieved in the same and the was retrieved in the same adjust your right margin to .3, as this will prevent "wrapping".
		to the burshood down to the next line.
•	Wrapped Aminos	The amino acid number/lext at the end of each line "wrapped" down to the next line.
		This may occur if your nie was retrieved in the wastern and th
		The rules require that a line not exceed 72 characters in length. This includes spaces.
3	Incorrect Line Length	The rules require that a line not exceed to state the second to st
		All text must be visible on page.
		The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs.
4	Misaligned Amino Acid	The numbering under each 5th amino acid is misaligned. This may be caused by a second between the numbers, between the numbering. It is recommended to delete any tabs and uses spacing between the numbers.
	Numbering	Detween the numbers.
		This file was not saved in ASCII (DOS) text, as required by the Sequence Rules. This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
5	Non-ASCII	This file was not saved in ASCII (DOS) lext, as required by the Sequence state. Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
		The state of the s
_	Variable Length	Sequence(s) contain n's or Xaa's which represented more than one residue.
6	_ Variable Cong	Sequence(s) contain n's or Ada's Willotte As per the rules, each n or Xaa can only represent a single residue. As per the rules, each n or Xaa can only represent a single residue having variable length and
		As per the rules, each n or Xaa can only represent a single having variable length and Please present the maximum number of each residue having variable length and Please present the maximum number of each residue having variable length and Please present a single having variable length and Please present the maximum number of each residue having variable length and Please present the maximum number of each residue having variable length and Please present the maximum number of each residue having variable length and Please present the maximum number of each residue having variable length and Please present the maximum number of each residue having variable length and Please present the maximum number of each residue having variable length and Please present the side of the present the pres
		indicate in the (ix) features section that some
		Sequence(s) contain amino acid or nucleic acid designators which are not standard
7	_ Wrong Designation	Sequence(s) contain amino acid or nuclear as set of the sequence Rules (Please refer to paragraph 1.822) representations as per the Sequence Rules (Please refer to paragraph 1.822)
		representations as per the Sequence reserve
		Sequence(s) missing. If intentional, please use the following format for each skipped sequence:
8	Skipped Sequences	Sequence(s) INCORPATION FOR SEQ ID NO:X:
	(OLD RULES)	C2) INFORMATION FOR SEQ ID NO:X: (1) SEQUENCE CHARACTERISTICS:()() on old insert any headings under "SEQUENCE CHARACTERISTICS") (1) SEQUENCE CHARACTERISTICS:()() NO:X:
		(-I) SEQUENCE DESCRIPTION:SEQ TO NO.
		This sequence is intentionally skipped
		The state of the s
		Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
		Sequence(s) missing. If intentional, please use the following format for each skipped sequence.
٩	Skipped Sequences	Sequence(s) missing. If intentional, picaso as
	(NEW RULES)	<210> sequence id number
		<400> sequence id number
	1	000
	Use of N's or Xara's	Use of N's and/or Xaa's have been detected in the Sequence Listing.
10 <u>V</u>	Use of N's or Xara's	Use of <220> to <223> Is MANDATORY if n's or Xaa's are present.
	(NEW RULES)	020 01 2550. 10 ==-
		Sanconna at an anna an a
	Use of <213>Organism	n Sequence(s) are missing this mandatory field or its response.
11	(NEW RULES)	·•
		and associated headings.
12	Use of <220>Feature	Sequence(s) are missing the <220-Feature and associated headings. Use of <220- to <223- is MANDATORY if <213-ORGANISM is "Artificial" or "Unknown" List of <220- to <223- is MANDATORY if <213-ORGANISM is "Artificial" or "Unknown".
	(NEW RULES)	Use of <220> to <223> is MANDATORY if <2/30 (See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32)
	•	(See "Federal Register, 0/01/50, vol. 55,
		(Sec. 1.823 of new Sequence Rules)
		File submitted was in the alphabetical heading format of the Old Sequence Rules. This is invalid since the
13	Wrong Format	File submitted was in the alphabetical heading format of the Old Sequence Rules. This or Acid Disclosures Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Disclosures Requirements for Patent Applications Containing 1, 1998, p. 29620
_	•	
		Federal Register Notice, Vol. 63, to 1, 1998. applies to applications filed on or after July 1, 1998.
		applies to applications field of the affect of the AKS-Biotechnology Systems Branch- 7/10/98